Primary Spinal Cord Oligodendroglioma with Postoperative Adjuvant Radiotherapy: A Case Report.
10.14245/kjs.2015.12.3.160
- Author:
Woon Tak YUH
1
;
Chun Kee CHUNG
;
Sung Hye PARK
Author Information
1. Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea. chungc@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Oligodendroglioma;
Spinal cord neoplasm;
Radiotherapy;
Chromosome 1p/19q co-deletion;
MGMT gene promoter methylation
- MeSH:
Diagnosis;
Drug Therapy;
Follow-Up Studies;
Humans;
Leg;
Magnetic Resonance Imaging;
Male;
Neoplasm, Residual;
Oligodendroglioma*;
Radiotherapy;
Radiotherapy, Adjuvant*;
Spinal Cord Neoplasms;
Spinal Cord*;
Young Adult
- From:Korean Journal of Spine
2015;12(3):160-164
- CountryRepublic of Korea
- Language:English
-
Abstract:
Primary spinal cord oligodendrogliomas are rare tumors comprising two percent of all spinal cord tumors. Although a treatment guideline has yet to be established, maximal surgical resection is primary in the treatment of spinal cord oligodendrogliomas. Adjuvant radiotherapy has remained controversial, and it is unclear whether chemotherapy adds any benefit. In this case report, the authors present a 24-year-old male who had a seven-year history of left leg weakness and a radiating pain in both legs. Magnetic resonance image (MRI) showed an intramedullary mass at the T4-T8 level. He underwent subtotal removal of the tumor and pathologic diagnosis revealed a WHO grade II oligodendroglioma. The patient was treated with radiotherapy postoperatively and followed up with MRI annually. Clinical and radiological status of the patient had been stationary for four years after the surgery. The five-year follow-up MRI showed an increase in the size and extent of the residual tumor. Despite radiological progression, considering that symptoms and the performance status of the patient had remained unchanged, further treatment has not been performed. Given the clinical outcome of this patient, close observation after subtotal removal with adjuvant radiotherapy is one of the acceptable treatment options for WHO grade II spinal cord oligodendrogliomas.
